Burning Rock has developed OverC™, a cutting-edge method for multiple cancer screening through blood testing.
The test is used to find many cancers in persons with average risk between the ages of 50 and 75, including esophagus, liver, lung, ovarian, and pancreatic cancers.
The OverC™ MCDBT demonstrated a 69.1% rate of sensitivity and a 98.9% rate of specificity in the results from the THUNDER case-control trial.
Certain medical devices that enable more effective treatment or detection of fatal or permanently disabling diseases or conditions, such as cancer, are given the Breakthrough Device Designation under the FDA's Breakthrough Devices Program.
This initiative aims to give patients and healthcare professionals quick access to medical devices that have received the designation, by accelerating their creation, evaluation, and review.
When compared to traditional cancer screening approaches, liquid biopsy offers the potential to increase cancer detection, early diagnosis, and treatment, improving survival and quality of life while lessening other disease-related burdens.
